Sector News

Amgen to cut 149 staff in retreat from neuroscience R&D

November 12, 2019
Life sciences

Amgen has given notice of its intent to lay off 149 people at its Cambridge, Massachusetts, operation by the end of the year. The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations in a move that would threaten around 180 jobs.

That plan became official Friday when state authorities in Massachusetts revealed Amgen had submitted a Worker Adjustment and Retraining Notification Act note. The note formally signaled Amgen’s intent to cut 149 employees in Cambridge loose at the end of the year. Amgen will retain an operations and process development presence in Massachusetts but is consolidating research back in California.

Amgen focused its Cambridge research site on neuroscience and hired people versed in medicinal chemistry, pharmacokinetics and drug metabolism, genetics, cell biology and and toxicology to staff it. With Amgen exiting neuroscience research, those skills are now largely surplus to requirements.

The move to exit neuroscience R&D follows the decision by Amgen and its partner Novartis to stop pivotal tests of CNP520 in Alzheimer’s disease. Amgen and Novartis pulled the plug on the program after an interim review linked the BACE inhibitor to a worsening of cognitive function.

While Amgen is pulling out of in-house neuroscience research, the company has plans to continue to participate in the field in some way. Amgen believes its work with deCODE positions it to understand the genetics of neurological disorders, and, while it wants to focus its internal resources elsewhere, it’s keen to capitalize on these capabilities in some way.

“Half the genes in the body are expressed in the brain and only the brain and we think we have some unique resources to try to capitalize on insights around that. We’ll be exploring potentially different models for doing that with venture capital and perhaps academic institutions as well,” Amgen CEO Bob Bradway said on a quarterly results conference call with investors late last month.

Amgen’s decision to exit neuroscience follows the shuttering of an Eli Lilly facility focused on the field and the spinning out of Pfizer’s pipeline to create Cerevel Therapeutics.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”